GSK names chief medical officer
GlaxoSmithKline recruits Pfizer Licensing, Worldwide Business Development VP Ellen Strahlman as chief medical officer. An ophthalmologist, Strahlman also previously worked as chief medical officer and global head of R&D for Bausch & Lomb and was CEO of ViroGen, a biotech firm. Announcing the appointment, GSK R&D Chairman Moncef Slaoui cites Strahlman's medical expertise and business development experience as key attributes. Her selection points to GSK's emphasis on seeking external R&D candidates to continue its licensing push
You may also be interested in...
Grant from Department of Commerce Market Development Cooperator Program funds project for four years. In addition to grant, the project partners – UNPA, National Animal Supplement Council, Eurofins Scientific testing company and China Inspections and Testing Society – get DoC assistance.
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.